CTOs on the Move

MARATHONLS

www.marathonls.com

 
Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

GeneSage

GeneSage is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Senseonics

Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring ("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.

22nd Century Fox

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Indevus Pharmaceuticals

Indevus Pharmaceuticals Inc. is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.